In order to strengthen its R&D activity and expand operations in the US market, Unichem Laboratories has lined up capex of around Rs 350 crore for the next two years. The company, which focuses on various therapeutic segments like gastroenterology and cardiology, expects its US revenues to cross $100 million over the next few years. The long term aim of the company is to cross $500 million in revenues from the US operations.
Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world.
